Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $46.00 price target on the stock. HC Wainwright's price target points to a potential upside of 280.79% from the company's previous close.
A number of other equities analysts have also recently issued reports on the stock. Baird R W upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price for the company. Raymond James raised Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Finally, Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $47.46.
Read Our Latest Analysis on Dyne Therapeutics
Dyne Therapeutics Stock Performance
DYN traded down $0.18 on Monday, hitting $12.08. 2,328,438 shares of the company were exchanged, compared to its average volume of 1,342,075. Dyne Therapeutics has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The firm has a market capitalization of $1.37 billion, a P/E ratio of -3.39 and a beta of 1.11. The business's fifty day moving average is $13.68 and its 200 day moving average is $24.49.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. Analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.
Insider Buying and Selling at Dyne Therapeutics
In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 6,237 shares of company stock valued at $77,760 over the last three months. 20.77% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE lifted its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after buying an additional 1,212 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Dyne Therapeutics during the third quarter worth about $1,588,000. Victory Capital Management Inc. lifted its stake in shares of Dyne Therapeutics by 59.4% in the third quarter. Victory Capital Management Inc. now owns 30,537 shares of the company's stock worth $1,097,000 after acquiring an additional 11,385 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in Dyne Therapeutics by 4.3% in the third quarter. Oppenheimer & Co. Inc. now owns 40,091 shares of the company's stock valued at $1,440,000 after purchasing an additional 1,636 shares during the last quarter. Finally, KBC Group NV grew its stake in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
